On August 25, 2020, the Cooperation Initiation Conference of Interventional VAD Project between Suzhou magAssist Medical Technology Co., Ltd. (“magAssist”) and Zhongshan Hospital, Fudan University (“Zhongshan Hospital”) was successfully held in the National Clinical Research Center for Radiology and Therapeutics, Zhongshan Hospital.
This initiation conference was joined by the clinical expert team led by Junbo GE, academician of the Chinese Academy of Sciences, director of Shanghai Institute of Cardiovascular Diseases and director of the Department of Cardiology of Zhongshan Hospital, and the magAssist R&D team led by Professor Po-Lin HSU, founder and CEO of magAssist, totaling about 20 persons.
Academician Junbo GE, Chief Scientist of the Project, Offered Guidance Suggestions on magAssist’s Principled Prototype
At the Initiation Conference, both parties introduced their respective team. Then magAssist R&D engineer team demonstrated the principled prototype, which sparked a heated discussion. Mr. GE and his clinical expert team put forward key suggestions for clinical application scenarios on the VAD R&D technical plan. The clinical indicators, design goals and R&D plan were also specified in the conference.
There are more than 1 million coronary interventional operations performed in China every year. With the progress of society and aging of population, the number of operations is growing year by year, and the patients’ conditions are increasingly complex. An interventional circulatory assist device is a miniaturized blood pump that can be inserted into the aorta through peripheral vascular interventional surgery, so as to provide rapid and non-invasive circulatory support in the event of heart pumping function failure. For intraoperative cardiac protection during high-risk coronary interventions, as well as for patients with cardiogenic shock caused by acute myocardial infarction, it is undoubtedly a strong line of defense against death, and the most challenging technology among all cardiovascular interventional devices.
Zhongshan Hospital represents the top level of cardiology in China. Under the leadership of Mr. GE, the expert team of Zhongshan Hospital has been constantly challenging the technical peak in coronary intervention for the benefit of patients. Through the integration of medical and engineering advantages, magAssist and Zhongshan Hospital will strive to overcome the “last mile” difficulty of cardiovascular interventional therapy, and jointly develop domestically made high-end medical devices for the vast number of patients with cardiovascular diseases in China and even in other parts of the world.
A Photo of Major Members of the Clinical and R&D Teams